Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of March due to the new share issue carried out to ensure delivery of performance shares within the framework of the long-term incentive programme that was resolved by the extraordinary general meeting on 12 November 2018. A total of 211,048 shares and votes have been added.
At 29 March 2019, which is the last trading day in March, the number of shares and votes in the Company amounts to 23,117,963. All shares are ordinary shares.
For further information, please contact:
Anders Lundin, CFO and IR
Telephone: +46 706 00 15 20
This information is information that Q-linea AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on 29 March 2018 at 08.30 AM CET
Q-linea AB is a diagnostics company focused on developing and delivering solutions for healthcare providers, enabling them to accurately diagnose and treat infectious diseases in the shortest possible time. Our core product, ASTar™, is a system for rapid and automatic determination of the most effective antibiotic treatment against infectious diseases. The Company was founded in 2008 and its operations were based on technology developed by scientists from the Rudbeck Laboratory at Uppsala University, together with other companies such as Olink Bioscience AB and Uppsala University’s holding company, UUAB.